Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 29:2010:698960.
doi: 10.4061/2010/698960.

Differential toxicity of DNA adducts of mitomycin C

Affiliations

Differential toxicity of DNA adducts of mitomycin C

Jill Bargonetti et al. J Nucleic Acids. .

Abstract

The clinically used antitumor agent mitomycin C (MC) alkylates DNA upon reductive activation, forming six covalent DNA adducts in this process. This paper focuses on differential biological effects of individual adducts in various mammalian cell cultures, observed in the authors' laboratories. Evidence is reviewed that various adducts are capable of inducing different cell death pathways in cancer cells. This evidence is derived from a parallel study of MC and its derivatives 2,7-diaminomitosene (2,7-DAM) which is the main metabolite of MC and forms two monoadducts with DNA, and decarbamoyl mitomycin C (DMC), which alkylates and crosslinks DNA, predominantly with a chirality opposite to that of the DNA adducts of MC. Specifically, 2,7-DAM is not cytotoxic and does not activate the p53 pathway while MC and DMC are cytotoxic and able to activate the p53 pathway. DMC is more cytotoxic than MC and can also kill p53-deficient cells by inducing degradation of Checkpoint 1 protein, which is not seen with MC treatment of the p53-deficient cells. This difference in the cell death pathways activated by the MC and DMC is attributed to differential signaling by the DNA adducts of DMC. We hypothesize that the different chirality of the adduct-to-DNA linkage has a modulating influence on the choice of pathway. Future studies will be directed to elucidate mechanisms of MC- and DMC-DNA adduct signaling in a structure-dependent context.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of MC, DMC, and 2,7-DAM. (Reproduced with permission from Chem. Res. Toxicol. 2008, 21, 2370).
Figure 2
Figure 2
Chemical structure of six major adducts of reductively activated MC. (Reproduced with permission from the reference in Figure 1.
Figure 3
Figure 3
Chemical structures of major adducts of DMC. (Reproduced with permission from the reference in Figure 1.
Figure 4
Figure 4
Frequencies of DNA adducts formed in MCF-7 human breast cancer cells treated with 10 μM MC (gray bars) or 10 μM DMC (black bars) for 24 hours under aerobic conditions. The individual frequency values of the bars are indicated above the bar error limits. Error limits are shown in % relative standard deviation units. (Reproduced with permission from the reference In Figure 1.

References

    1. Hata T, Hoshi T, Kanamori K, et al. Mitomycin, a new antibiotic from Streptomyces. I. The Journal of Antibiotics . 1956;9:141–146. . - PubMed
    1. Carter SK, Crooke STE. Mitomycin C: Current Status and New Developments . New York, NY, USA: Academic Press; 1979. .
    1. Iyer VN, Szybalski W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proceedings of the National Academy of Sciences of the United States of America . 1963;50:355–362. . - PMC - PubMed
    1. Armstrong RW, Salvati ME, Nguyen M. Novel interstrand cross-links induced by the antitumor antibiotic carzinophilin/azinomycin B. Journal of the American Chemical Society . 1992;114(8):3144–3145. .
    1. Tomasz M, Lipman R, Chowdary D. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science . 1987;235(4793):1204–1208. . - PubMed